Global Nuclear Medicine Therapeutics Market Worth USD 2.38 Billion by 2020 - Analysis, Technologies & Forecasts Report 2015-2020 - Vendors: IBA Group, Triad Isotopes, NTP Radioisotopes - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Nuclear Medicine Therapeutics Market (Alpha Emitters, Beta Emitters and Brachytherapy) - Analysis and Forecasts (2015-2020)" report to their offering.

The global nuclear medicine therapeutics market is expected to grow from an estimated $1.24 billion in 2015 to $2.38 billion in 2020, at an estimated compound annual growth rate (CAGR) of 13.91%.

Major factors for the growth of the market are increasing use of SPECT and PET analysis in radiopharmaceuticals, increased awareness of people for radiopharmaceuticals, and ready availability of radiopharmaceuticals. Novel applications such as Alzheimers and continually expanding oncology application segment also drive the market. However, some of the major constrains of the market are complex FDA toxicology and other regulatory requirements, lack of specific guidelines from the FDA for good manufacturing practices of radiopharmaceuticals, lack of consensus for standardized image acquisition in nuclear imaging procedures.

Therapeutic nuclear medicine finds its application in treatment of various types of cancer such as lymphoma, bone metastasis, thyroid, endocrine tumors etc. Radionuclide therapy has unique promise as a vehicle for personalized treatment of cancer. Alpha emitters which use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases.

Companies Mentioned:

  • IBA Group
  • Lantheus Medical Imaging
  • Triad Isotopes
  • Siemens Healthcare (PETNET Solutions)
  • NTP Radioisotopes

Report Structure:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Market Segmentation by Geography

9.Competitive Landscape

10. Key Vendor Analysis

11. Analyst Outlook for Investment Opportunities

12. Future Outlook of the Market

For more information about this report visit http://www.researchandmarkets.com/research/7l2k25/global_nuclear

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Nuclear Medicine and Radiopharmacology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Nuclear Medicine and Radiopharmacology